How will Meta's nuclear deal impact AI energy use?
Why did Nvidia regain title as top valued company?
What effect will Trump's steel and aluminum tariffs have?
How is South Korea's new president shaping trade policy?
Why are auto makers concerned about China's mineral export curbs?
What caused CrowdStrike's revenue forecast to weaken?
How are US job openings rising amid trade tensions?
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response
benzinga.com/news/health-care/25/06/45724030/kymera-therapeutics-says-atopic-dermatitis-potential-matches-sanofi-regenerons-blockbuster-dupix
Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Monday revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral STAT6 degrader medicine.
The findings significantly surpassed the company’s expectations, demonstrating robust STAT6 degradation and a…
This story appeared on benzinga.com, 2025-06-02 14:29:24.